164 related articles for article (PubMed ID: 31070502)
1. Spontaneous multiple cervical artery dissections after alemtuzumab.
Durand-Dubief F; Marignier R; Berthezene Y; Cottin J; Nighoghossian N; Vukusic S
Mult Scler; 2020 Mar; 26(3):381-383. PubMed ID: 31070502
[TBL] [Abstract][Full Text] [Related]
2. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
Ahrabian D; Neill L; Bell R; Leary SM
Mult Scler; 2020 May; 26(6):735-737. PubMed ID: 32298216
[TBL] [Abstract][Full Text] [Related]
3. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
4. Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis.
Brannigan J; Jones JL; Stacpoole SRL
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32522766
[No Abstract] [Full Text] [Related]
5. Clinical observation during alemtuzumab administration.
Allen CM; Feng JJ; Willis MD; McGinley M; Ontaneda D; Tallantyre EC; Evangelou N
Mult Scler Relat Disord; 2020 Jan; 37():101412. PubMed ID: 32172992
[No Abstract] [Full Text] [Related]
6. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.
Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I
Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912
[TBL] [Abstract][Full Text] [Related]
7. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Romba MC; Newsome SD; McArthur JC
Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
[TBL] [Abstract][Full Text] [Related]
8. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
Whiteside D; Barth S; Datta A; Trip SA
Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
[TBL] [Abstract][Full Text] [Related]
9. Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.
Russo CV; Saccà F; Paternoster M; Buonomo AR; Gentile I; Scotto R; Brescia Morra V; Mansueto G
Mult Scler; 2020 Jan; 26(1):123-126. PubMed ID: 30882274
[No Abstract] [Full Text] [Related]
10. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
[TBL] [Abstract][Full Text] [Related]
11. Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report.
Romero A; Midaglia L; Salcedo MT; Viladomiu L; Guillén E; Bajaña I; Escolà-Vergé L; Tintoré M; Montalban X; Len O
Mult Scler Relat Disord; 2020 May; 40():101973. PubMed ID: 32028116
[TBL] [Abstract][Full Text] [Related]
12. A case of anaphylaxis to alemtuzumab.
Nye CJS; Wagner A; Kousin-Ezewu O; Jones JL; Coles AJ
J Neurol; 2019 Mar; 266(3):780-781. PubMed ID: 30715557
[No Abstract] [Full Text] [Related]
13. Case of alemtuzumab-related alopecia areata management in MS.
Chan JK; Traboulsee AL; Sayao AL
Neurol Neuroimmunol Neuroinflamm; 2019 Jan; 6(1):e516. PubMed ID: 30568994
[No Abstract] [Full Text] [Related]
14. Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis.
Lau AY; Lui GCY; Chan KP; Au C; Mok VCT; Ziemssen T
Mult Scler Relat Disord; 2020 Feb; 38():101503. PubMed ID: 31743846
[TBL] [Abstract][Full Text] [Related]
15. Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration.
Hoffman BM; Zeid NA; Alam U; Caress JB
Mult Scler Relat Disord; 2019 Jan; 27():131-132. PubMed ID: 30384197
[TBL] [Abstract][Full Text] [Related]
16. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
Ferraro D; Camera V; Vitetta F; Zennaro M; Ciolli L; Nichelli PF; Sola P
Neurology; 2018 May; 90(18):852-854. PubMed ID: 29602915
[No Abstract] [Full Text] [Related]
17. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
[No Abstract] [Full Text] [Related]
18. Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.
Lapucci C; Gualandi F; Mikulska M; Palmeri S; Mancardi G; Uccelli A; Laroni A
Mult Scler Relat Disord; 2018 Nov; 26():52-54. PubMed ID: 30223229
[TBL] [Abstract][Full Text] [Related]
19. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
Metz I; Rieckmann P; Kallmann BA; Brück W
Acta Neuropathol Commun; 2016 Aug; 4(1):81. PubMed ID: 27503238
[No Abstract] [Full Text] [Related]
20. A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.
Rolfes L; Pfeuffer S; Ruck T; Windhagen S; Oschlies I; Pavenstädt HJ; Angenendt L; Wiendl H; Krämer J; Meuth SG
Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31704887
[No Abstract] [Full Text] [Related]
[Next] [New Search]